TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC by Xiao-Mei Tang, Min-Min Shi, Jia-Cheng Wang, Yi-Jin Gu, Yu-Ting Dai, Qin-Xin Yang, Jia Liu, Ling-Jie Ren, Xin-Yun Liu, Chun Yang, Fang-Fang Ma, Ji-Bing Liu, Hong Yu, Da Fu, Yun-Feng Wang

Subjects: Get full text

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer by Jiahao Zhang, Jianying Lei, Caicong You, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li

Subjects: Get full text

Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report by Linn Z, Gu Z, Wang L, Cai S

Subjects: Get full text

PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib by Xin‐Yuan Lei, Kai‐Yue He, Qiu‐Tong Li, Lei Zhang, Dan‐Hui Wu, Jing‐Yu Yang, Jin‐Rong Guo, Meng‐Jie Liu, Zi‐Long Zhao, Jun‐Qi Li, Huai Liu, Yuan Zhao, Yu‐Jia Li, Qian‐Hui Sun, Chen‐Guang Wu, Yun‐Fan Wang, Geng‐Sheng Cao, Gang Wang, Yong‐Ping Jian, Zhi‐Xiang Xu

Subjects: Get full text